Firm reiterates commitment to relief Kano residents’ of nasal health burden
Kano market at the weekend welcomes a new solution to respiratory and other related challenges with the introduction of a new pharmaceutical brand manufactured to provide relief from cold and cough.
Recommended by medical experts as effective drugs produced to obstruct all forms of respiratory difficulties being contracted through atmospheric and environmental conditions, the new Konos, produced by a leading multinational pharmaceutical company tested is to effectively cure all nasal burden.
Speaking at the launch of the product at the weekend in Kano, the Country Manager of the pharmaceutical firm, Dhanang Riyo Anggoro, revealed that the medication was carefully produced as a double attack against cold and cough in Nigeria.
Anggoro noted that after a careful study that revealed cold and cough conditions as commonest infectious diseases in Nigeria, the company decided to produce Konos for the country’s market, to tackle health issues, inconveniences and stress caused by cold and cough.
He expressed optimism that the new drug, produced in the right solution, will help to curb the high rate of cough and other infections with limitation to four major medicinal advantages, including relieves from cold and coughs, sore throat, eases breathing, and soothes of nerve to ensure tender relax and recover from stress.
Senior Resident Doctor, Dr. Chinedu Aniobi, who also testified to the effectiveness of Kono, said the new product will efficiently relieve patients from cold and flu symptoms such as, nasal congestion, sneezing and dry cough.
Aniobi explained: “Human rhinovirus is responsible for 50-80 per cent of all common colds and the rest are caused by influenza, adenovirus, or enterovirus. Active cough is usually caused by common colds. Symptoms of cold such as sore throat, sneezing, running nose, and nasal congestion appear between one or two days after exposure to the virus.
“Konos is a unique brand with a double attack combination (antihistamine/analgesic/decongestant + an antitussive) for the treatment of cold and cough. Although cold and cough remain a major health challenge in our environment and the world at large, the advent of the novel and unique combination therapy in KONOS that is highly efficacious, cost-effective and with low side-effect profile bodes well for the treatment of this health challenge now and in the near future.”
Key business partners of the firm and major distributors, pharmacists, wholesalers and retailers from different parts of the country were at the launch to welcome the new product into the market.
No comments yet